Journal of cannabis research最新文献

{"title":"The power of zinc: excess and deficiency of Zn decrease cannabinoids in cannabis without Zn toxicity concerns to consumers.","authors":"Sivan Shiponi, Nirit Bernstein","doi":"10.1186/s42238-026-00404-0","DOIUrl":"10.1186/s42238-026-00404-0","url":null,"abstract":"<p><p>BACKGROUND: Some of the mineral nutrients essential for plants are heavy metals, which their consumption may involve health concerns to the consumers. Hence, for safe consumption, optimized fertilization protocol for cannabis plants needs to focus also on minimizing the accumulation of potentially toxic minerals in the inflorescences. Zinc is an essential microelement for plants that has a toxic effect on the human body when consume in high concentration. The present study aimed to understand the drug-type (medical) cannabis plant response to Zn supply, for identifying the optimal Zn supply that balance high quality production with safe product. METHODS: cannabis plants were grown under five Zn levels (0.05, 0.1, 0.35, 1.0, 4.0 mg L− 1) in controlled environment; and morpho-physiology analyses, cannabinoid profile, and ionome-profiling in the plant-organs were conducted. RESULTS: Increased level of Zn supply reduced the relative accumulation of Zn in the inflorescences, and excess Zn was stored in the plant root, and therefore does not impose additional health risk to consumers. Cannabinoid concentrations were highest under 0.35 mgL− 1 Zn supply, and decreased with further increase in Zn supply. The acidic cannabinoids THCA, CBDA, CBCA, CBDVA, THCVA increased with the increase in Zn supply up to 0.1–0.35 mgL− 1 and declined with further increase in Zn. Zn deficiency (under 0.05 mgL− 1 Zn supply) reduced physiological performance, plant growth and inflorescence yield, and stimulated uptake of Zn, P, S, Ca, Fe, and Mn. Symptoms of excess Zn were death of leaf tips; however plant performance was overall not affected by Zn excess. CONCLUSIONS: Excess Zn is retained in the root and excluded from the inflorescence, thereby not imposing health risk to the consumers. The recommended Zn concentration in the fertigation solution that was found to attain highest specialized-metabolite concentrations, and optimal yield and plant performance is 0.35 mgL− 1. </p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"8 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12961903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Not what it seems: analytical validation and label accuracy of commercial CBD oils using HPTLC.","authors":"Keilor Morales Alfaro, Gabriel Zamora, Manuel Sandoval-Barrantes, Ana Francis Carballo Arce, Jose A Rodriguez-Corrales","doi":"10.1186/s42238-026-00419-7","DOIUrl":"10.1186/s42238-026-00419-7","url":null,"abstract":"<p><p>The rapid growth of the cannabidiol (CBD) market has raised concerns about product labeling accuracy and quality control. This study aimed to validate a high-performance thin-layer chromatography (HPTLC) method and apply it to analyze CBD content in commercial oils and e-liquids available in Costa Rica. The HPTLC method was validated following guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. Performance parameters assessed included linearity, accuracy, precision, specificity, and limits of detection (LOD), and quantification (LOQ). After validation, the method was used to quantify CBD and screen for other phytocannabinoids such as CBG, CBN, and Δ⁹-THC in 5 commercial oils and 3 e-liquids. The method showed excellent linearity (R² > 0.9998), precision (%CV < 2%), and accuracy (99–102% recovery), while successfully detecting CBD concentrations and qualitatively identifying other cannabinoids. Notably, some commercial samples showed CBD over- and underlabeling, and tentative presence of Δ⁹-THC. These findings reveal inconsistencies between the labeled and actual CBD content in several products, mirroring international trends, and represent the first documented evidence of mislabeling in hemp-based products in Costa Rica. The validated HPTLC method offers a cost-effective tool for regulatory surveillance, enabling preliminary cannabinoid profiling and quantification. Its application can support public health policies and consumer protection through improved product transparency and compliance with Costa Rica’s national hemp regulations.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13072474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147367998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in cannabis urine drug screen testing in Colorado's largest health system: a retrospective cohort study.","authors":"Brock J Gilsdorf, Laura J Helmkamp, Robert L Page, Larry A Allen, Colleen K McIlvennan","doi":"10.1186/s42238-026-00418-8","DOIUrl":"10.1186/s42238-026-00418-8","url":null,"abstract":"<p><p>BACKGROUND: Colorado was the first state in the United States to legalize recreational cannabis, which provides a unique opportunity to evaluate cannabis urine drug screen (UDS) testing trends in a large healthcare system in response to that policy. This study examined how testing rates and positivity evolved over time and whether testing patterns varied by demographic factors. METHODS: In this retrospective cohort study, we analyzed all University of Colorado Health visits from 2008 to 2022 using electronic medical record data. We assessed group comparisons with Chi-squared tests and t-tests and demographic predictors of UDS testing using multivariable log binomial models. RESULTS: From 2008 to 2022, the positivity rate for cannabis among UDSs rose from 14% in 2008 to 30% in 2015, then plateaued. The proportion of visits with cannabis testing declined from 0.25% to 0.04%. Younger patients, males, and individuals identifying as Black, Hispanic, or American Indian were more likely to be tested than their counterparts, with notable racial and ethnic disparities. CONCLUSIONS: Despite rising cannabis positivity rates, testing frequency declined. Persistent demographic disparities in testing raise concerns about potential bias, especially in the absence of documented differences in use across groups. Future work should examine indications for cannabis urine drug screen testing and how results influence clinical care. </p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13063531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Driving by frequent cannabis users 'the morning after' last use of smoked cannabis: an observational driving simulator study.","authors":"Christina Zakala, Sampson Zhao, Alex Battistuzzi, Adrien Nette, Justin Matheson, Bernard Le Foll, Bruna Brands, Christine M Wickens, Pamela Kaduri, Omer Hasan, Wei Wang, Sheng Chen, Patricia Di Ciano","doi":"10.1186/s42238-026-00416-w","DOIUrl":"10.1186/s42238-026-00416-w","url":null,"abstract":"<p><p>BACKGROUND: It is well-established that cannabis can affect driving in the hours after cannabis use, but the exact duration of these effects, and relationship with delta-9-tetrahydrocannabinol (THC) concentrations in blood and oral fluid, remains to be determined. METHODS: Frequent (≥ 4 times a week) users of smoked cannabis drove a simulator the morning after (12-15 hours) last use of smoked cannabis; a control group of non-cannabis users matched for age and sex was also included. Concentrations of THC, cannabidiol (CBD) and metabolites were measured in oral fluid and blood at the time of the drive. RESULTS: In total, 65 participants (mean age 30 years; 33 males) in each group completed all study procedures. Participants were generally well-matched (age, sex, driving experience, amount of driving per year/week, hours of sleep) but differed in racial breakdown and years of education. Under both standard and dual task (distacted) conditions, standard deviation of lateral position (SDLP) was higher in the control group (standard: 0.305 meters; dual task: 0.272 meters; n=65) compared to the cannabis group (standard: 0.28 meters; dual task: 0.256 meters; n=65); these differences were small (Cohen’s d -0.389 (standard) and -0.359 (dual task)) and were not significant after correction for multiple comparisons. Measures of speed and following distance were not impacted. Neither blood nor oral fluid THC, CBD or metabolites was significantly correlated with any measure of driving after correction for multiple comparisons; mean concentrations of blood THC was above 2 ng/mL. After correction for multiple comparisons, trends between driving and concentrations of the psychoactive metabolite 11-hydroxy-THC (11-OH-THC) were found. Participants who smoked cannabis the night before reported higher levels of subjective intoxication, and more willingness to drive before the drive, that was not significant after correction for multiple comparisons. CONCLUSIONS: The regular cannabis use group showed no significant impairment in driving performance 12-15 hours after last cannabis use the night before, compared to the control group. Blood and oral fluid THC concentrations may not be an accurate correlate of driving behavior. Large-scale studies are needed to determine whether less frequent users are impaired the morning after last use, and whether the present findings also extend to different routes of administration. </p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13127016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of cannabidiol supplementation in mitigating lipid precursors of inflammation in hepatic steatosis progression.","authors":"Karolina Konstantynowicz-Nowicka, Mateusz Zwierz, Piotr Franciszek Kurzyna, Magdalena Zabielska-Kaczorowska, Klaudia Sztolsztener, Adrian Chabowski, Ewa Harasim-Symbor","doi":"10.1186/s42238-026-00413-z","DOIUrl":"10.1186/s42238-026-00413-z","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the effects of cannabidiol (CBD) on early-stage inflammation, a key factor in the progression of liver diseases from metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis (MASH) and irreversible cirrhosis. The study focused on CBD's influence on the pro-inflammatory n-6 and anti-inflammatory n-3 pathways, on arachidonic acid (AA) levels as an early marker of inflammation, and the expression of enzymes involved in AA metabolism, as well as inflammatory cytokines and chemokines.</p><p><strong>Methods: </strong>Forty male Wistar rats were randomly divided into four groups: control (C)-fed a standard diet and treated with cannabidiol vehicle for the last 14 days, control + cannabidiol (C + CBD) - fed a standard diet and treated with CBD for the last 14 days, high-fat diet (HFD) - fed a high-fat diet and treated with cannabidiol vehicle for the last 14 days, high-fat diet + cannabidiol (HFD + CBD)-fed a high-fat diet and treated with cannabidiol for the last 14 days. At the end of the treatment period, all the rats were fasted for 24 h, anesthetized, and sacrificed. Gas-liquid chromatography was used to measure n-6 and n-3 pathway polyunsaturated fatty acids (PUFAs) activities and AA levels in lipid fractions in the liver. The Multiplex immunoassay assessed cytokine and chemokine content in liver tissue, while Western Blot analyzed the expression of selected enzymes.</p><p><strong>Results: </strong>Initial findings indicated CBD's potential in reducing inflammation and its therapeutic efficacy in preventing MASH development induced by HFD. The results indicated that supplementing with CBD led to a decrease in the n-6 PUFA pathway, known for its pro-inflammatory effects, and an increase in the anti-inflammatory n-3 PUFA pathway. These changes were simultaneous with lower levels of arachidonic acid, which is crucial for the formation of inflammatory mediators. CBD influenced the expression of enzymes like COX-1 and COX-2 involved in AA metabolism and reduced the levels of pro-inflammatory cytokines.</p><p><strong>Conclusions: </strong>Our observations confirmed that CBD, which affects early indicators of inflammation, has the potential to become a new and safe, promising supportive drug for hepatic inflammation and steatosis treatment.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13041381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II randomized controlled trial comparing traditional Thai cannabis-based medicine with lorazepam for insomnia treatment.","authors":"Thavatchai Kamoltham, Suwadee Chokchaisiri, Chawalit Yongram, Panupan Sripan, Surasak Im-Iam, Panupong Sanasit, Varanon Intaravattana, Chatchai Sawasdichai, Patpong Udompat, Tanawat Chaiphongpachara, Tanawan Kummalue","doi":"10.1186/s42238-026-00415-x","DOIUrl":"10.1186/s42238-026-00415-x","url":null,"abstract":"<p><strong>Background: </strong>A traditional Thai cannabis-based multi-herbal formulation is legally recognized in Thailand for therapeutic use and clinical research. However, clinical evidence supporting its use for insomnia remains limited.</p><p><strong>Methods: </strong>This Phase II randomized, double-blind, active-controlled non-inferiority trial compared the efficacy and safety of the Anti-Pom-Leung Fever medicine with lorazepam in patients with chronic insomnia. One hundred participants were randomized to receive either the herbal formulation or lorazepam for 4 weeks. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Non-inferiority was evaluated at week 4 using a predefined margin of 2.1 based on the upper bound of the two-sided 95% confidence interval for the mean PSQI difference (experimental minus comparator). Longitudinal changes were analyzed using repeated-measures analysis of variance, and safety was evaluated through clinical and laboratory assessments.</p><p><strong>Results: </strong>Eighty-two participants completed the study (41 per group). Baseline characteristics were comparable between groups. Both treatments significantly improved sleep quality over 4 weeks. At week 4, mean PSQI scores were 3.44 in the experimental group and 4.78 in the comparator group, with a mean difference of -1.34 (95% CI: -2.99 to 0.31), demonstrating non-inferiority. A significant main effect of time on PSQI scores was observed, with no significant time-by-treatment interaction. Quality of life and stress improved in both groups, and safety profiles were comparable, with no clinically significant adverse effects.</p><p><strong>Conclusions: </strong>The traditional Thai cannabis-based multi-herbal formulation demonstrated non-inferior efficacy to lorazepam and was well tolerated, supporting its use as a short-term alternative for chronic insomnia.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13040682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis: from crop to shop-some insights about stability to access quality control.","authors":"Claudete da Costa-Oliveira, João Gabriel Gouvêa-Silva, Raoul Dos Santos Fernandes Muniz, Jéssica Sales Felisberto, Priscila Gava Mazzola, Renato Crespo Pereira, Davyson de Lima Moreira, Ygor Jessé Ramos","doi":"10.1186/s42238-026-00409-9","DOIUrl":"10.1186/s42238-026-00409-9","url":null,"abstract":"<p><p>BACKGROUND: Cannabis sativa L. is increasingly used for medicinal and commercial purposes, yet most reviews treat chemical composition, ecology, and post-harvest processing as separate topics. This manuscript advances a conceptual framework that links chemical stability, chemodiversity, and post-harvest quality across the production chain (“crop to shop”), emphasizing and detailing how environmental and technological drivers shape cannabinoid and terpenoid profiles and, ultimately, product standardization. METHODS: We conducted a structured scoping review with bibliometric mapping of studies on volatile oils from inflorescences (1963–2025), applying explicit eligibility criteria and extracting metadata on genotype, collection site, plant state, extraction procedure, and analytical platforms. To synthesize chemical patterns, we employed exploratory chemometric summaries (principal component analysis and hierarchical grouping) and comparative narrative analyses of pre- and post-harvest factors (e.g., drying, grinding, extraction, storage, and others), and their implications for stability and quality assessment. RESULTS: Across regions, chemical stability emerged as the central axis organizing chemodiversity, ecological roles, and quality outcomes. Pre-harvest conditions (cultivar, environment, phenology, and others) and post-harvest practices (drying regimes, particle size, extraction choices, storage conditions such as temperature, light, oxygen, and moisture) consistently redirected volatile and non-volatile profiles, with predictable formation or loss of key markers. The mapping highlights geographic concentration of research in Europe, the underrepresentation of the Americas, Oceania, and Africa, and limited coverage of minor cannabinoids and oxygenated terpenoids despite their technological relevance. The synthesis clarifies when technological steps favor sesquiterpenes versus monoterpenes, how trichome integrity protects active compounds, and why water activity and packaging permeability are decisive for stability. This review also identifies operational gaps regarding winterization parameters, sterilization impacts, and the scale-up of greener extraction methods. CONCLUSIONS: By integrating phytochemistry, chemical ecology, and stability science, this review proposes a stability–chemodiversity–quality framework that distinguishes this approach from prior reviews. The framework supports actionable guidelines for cultivation choices, post-harvest handling, extraction designs, packaging, and storage to improve reproducibility and labeling accuracy. It also sets priorities for future research: standardized stability testing across matrices, inclusion of minor constituents, ecologically informed phenology, and validation of processing models based on moisture dynamics and oxygen control. </p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of metals, pesticides, mycotoxins, microbial contaminants and THC potency in illegal and regulated cannabis inflorescences in Canada.","authors":"Quinton Fiering, Jordyn Mackey, Hayline Kim, Yousef Risha, Ryan Denkert, Monica Iuogovaz, Gabriela Zorila, Julia Killorn, Gayel Abi-Yaghi, Emmanuelle Bahl, Josée Verreault, Marick Gagnon, Carl Rodrigue, Roxane Arsenault, Julio Bran Barrera, Maude Lord, Jamile Ahmarani, Diana Becerra Rodriguez, Arianne Gauthier, Diana Bran Barrera, Cathy St-Laurent, Guillaume Massicotte, Roland Yang, Morgan Popplewell, Michel Blais, Peter Bradley, Cecile Le, William Mohan, André Robichaud, Catherine Deschenes, Isabelle Disnard, Geneviève Clément, Maryse Fontaine, Irène Iugovaz, Julie Bellemare, David R Blais","doi":"10.1186/s42238-026-00414-y","DOIUrl":"10.1186/s42238-026-00414-y","url":null,"abstract":"<p><p>BACKGROUND: Following the legalization of recreational cannabis in Canada under the Cannabis Act (2018), regulatory frameworks were implemented to ensure product safety, quality, and consistency within the legal market. Previous studies revealed significantly greater pesticide contamination in illegal cannabis than in legal products. In light of these findings, the present study expands contaminant surveillance to include the quantification of Δ⁹-tetrahydrocannabinol (THC) and a broader range of potential toxicants, including metals, pesticides, mycotoxins, and microbial agents. METHODS: Fifty legal cannabis products were purchased across Canadian provinces, and 50 illegal samples were obtained via law enforcement seizures. All the samples were tested via validated, accredited/attested methods. THC content was assessed using LC-UV-MS. Pesticides were analyzed via LC-MS/MS and GC-MS/MS; metals via ICP-MS/MS; mycotoxins via LC-MS/MS; and microbial contamination using MALDI-TOF. RESULTS: THC levels in 48% of legal products deviated by more than 20% from their labeled concentrations. Microbiological testing revealed that 20% of legal products exceeded the European Pharmacopoeia microbial limits, prompting appropriate compliance and enforcement measures to address each of these cases. In contrast, 55% of the illegal products exceeded the aerobic plate count thresholds, and 73% surpassed the yeast and mold limits. Mycotoxins were undetected in legal products but were present in 12% of illegal samples. Pesticide residues were found at trace levels (0.01 µg/g) for myclobutanil and dichlobenil in two legal samples, whereas 94% of illegal samples contained pesticides, averaging 3.4 compounds per sample across 24 unique active ingredients. Metal analysis revealed higher levels of arsenic, cadmium, lead, and mercury in illegal products than in their legal counterparts. However, legal samples presented higher chromium concentrations, with peak values approximately threefold greater than those observed in illegal cannabis. The concentrations of arsenic, barium, chromium, copper, molybdenum, nickel, and vanadium exceeded the inhalation concentration limits found in Table 2 of USP <232> of the United States Pharmacopeia (USP) in one or both product categories. CONCLUSION: These findings demonstrate that legal THC levels differ from their label claims as well as that contaminants differ between legal and illegal cannabis products. The results provide evidence to inform regulatory oversight, enhance risk assessment efforts, and support informed decision-making by consumers and policymakers in the context of a legal cannabis framework. </p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13045130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147277785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing machine learning and multivariate analysis to explore global trends in Cannabis sativa research.","authors":"Javier De La Hoz-M, Karime Montes-Escobar, Carlos Alfredo Salas-Macias","doi":"10.1186/s42238-026-00397-w","DOIUrl":"10.1186/s42238-026-00397-w","url":null,"abstract":"<p><p>This study employs advanced data science techniques to explore global research trends in Cannabis sativa from 1974 to 2024. This research integrated bibliographic datasets from PubMed, Scopus, and Web of Science. By combining latent Dirichlet allocation (LDA) and HJ-Biplot methods, we extracted actionable insights from large-scale data to address the current gap in long-term global research monitoring. The analysis identified key research topics, geographic disparities, and temporal trends, providing a comprehensive overview of the evolution of Cannabis sativa studies. The results highlight an increasing focus on the medical applications of Cannabis sativa, particularly in North America and Europe, while highlighting research gaps in emerging regions such as Africa and South America. Furthermore, the integration of multivariate methods with machine learning offers a replicable framework for managing large bibliographic datasets and enhancing data-driven decision-making in research management. Additionally, combining topic modeling with multivariate visualization provides a novel framework to understand how research themes evolve and interact. This approach serves as a strategic tool for stakeholders navigating the rapidly changing cannabis field.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146260558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Micropropagation of Cannabis sativa: genetic and epigenetic stability assessment over multiple generations.","authors":"Vincent Lefebvre, Davoud Torkamaneh, Sylvie Deslauriers, Théo Devèze, Maxime de Ronne, Mélodie B Plourde, Mebarek Lamara, Hugo Germain","doi":"10.1186/s42238-026-00406-y","DOIUrl":"10.1186/s42238-026-00406-y","url":null,"abstract":"<p><strong>Background: </strong>Micropropagation is an increasingly sought-after propagation method in the cannabis industry as growers seek to maximize production efficiency, improve multiplication rates and cultivate plants that are free from biotic stress. However, knowledge about the impact of micropropagation on cannabis is still limited in the scientific literature, as most studies have primarily focused on optimizing environmental parameters and growth conditions.</p><p><strong>Methods: </strong>In vitro cultures of three cannabis cultivars (Critical Purple Kush, Green Crack, and Gelato) were initiated and maintained for 60 weeks with subcultures every three weeks. Leaf samples were collected at the start and after every five subcultures for DNA extraction, and the genomes were sequenced using 3D-GBS and EM-seq to identify genetic (SNPs) and epigenetic (DMPs) variations, followed by GO and KEGG pathway analyses.</p><p><strong>Results: </strong>The results revealed that genomic variants from our CPK (16,169), GC (15,472) and GEL (16,605) samples were mostly located within the intergenic regions. Mutations seem to mostly occur during culture initiation and the first five subcultures, plateauing afterwards up to the 20th subculture. Methylation sequencing revealed that DMPs were less frequent than SNPs, with differential methylation levels showing cultivar-specific patterns varying between CPK, GC and GEL with respectively 22%, 9% and 13% for promoter regions, 13%, 5% and 6% for exon regions, 4%, 4% and 3% for intron regions and 61%, 82% and 78% for intergenic regions. These results indicate a strong cultivar dependency of epimutation and suggest their potential phenotypic impact. GO and KEGG pathway enrichment analyses of genes harboring SNPs and DMPs revealed functional associations relevant to cannabis micropropagation.</p><p><strong>Conclusion: </strong>Our results highlight the importance of monitoring both genetic and epigenetic stability for long-term cannabis cultivation.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13020208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}